EXHIBIT
31.1 CERTIFICATION
OF THE CHIEF EXECUTIVE OFFICER I,
Daniel H. Movens, the Chief Executive Officer of Caraco Pharmaceutical
Laboratories, Ltd. (the registrant) certify that: 1.
I have
  reviewed this report on Form 10-K of the registrant;2.
Based on my
  knowledge, this report does not contain any untrue statement of a material
  fact or omit to state a material fact necessary to make the statements made,
  in light of the circumstances under which such statements were made, not
  misleading with respect to the period covered by this annual report;3.
Based on my
  knowledge, the financial statements, and other financial information included
  in this annual report, fairly present in all material respects the financial
  condition, results of operations and cash flows of the registrant as of, and
  for, the periods presented in this annual report;4.
The
  registrants other certifying officer and I are responsible for establishing
  and maintaining disclosure controls and procedures (as defined in Exchange
  Act Rules 13a-15(e) and 15d-15(e) and internal control over financial
  reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the
  registrant and have:(a)
Designed such disclosure
  controls and procedures, or caused such disclosure controls and procedures to
  be designed under our supervision, to ensure that material information
  relating to the registrant, is made
  known to us by others within those entities, particularly during the period
  in which this report is being prepared;(b)
Designed such internal
  control over financial reporting, or caused such internal control over
  financial reporting to be designed under our supervision, to provide
  reasonable assurance regarding the reliability of financial reporting and the
  preparation of financial statements for external purposes in accordance with
  generally accepted accounting principles;(c)
Evaluated the
  effectiveness of the registrants disclosure controls and procedures and
  presented in this report our conclusions about the effectiveness of the
  disclosure controls and procedures, as of the end of the period covered by
  this report based on such evaluation; and(d)
Disclosed in this report
  any change in the registrants internal control over financial reporting that
  occurred during registrants most recent fiscal quarter (registrants fourth
  fiscal quarter in the case of an annual report) that has materially affected,
  or is reasonably likely to materially affect, registrants internal control
  over financial reporting; and5.
The registrants other
  certifying officer and I have disclosed, based on our most recent evaluation
  of internal control over financial reporting, to the registrants auditors
  and the audit committee of the registrants board of directors (or persons fulfilling
  the equivalent functions):    (a)
All significant
  deficiencies and material weaknesses in the design or operation of internal
  control over financial reporting which are reasonably likely to adversely
  affect the registrants ability to record, process, summarize and report
  financial information; and(b)
Any fraud, whether or not
  material, that involves management or other employees who have a significant
  role in the registrants internal control over financial reporting.May 14, 2007/s/ Daniel
  H. MovensDaniel H.
  MovensChief
  Executive Officer